Koshkin V, De Oliveira M, Peng C, Ailles L, Liu G, Covens A
Mol Clin Oncol. 2021; 15(2):161.
PMID: 34295468
PMC: 8273925.
DOI: 10.3892/mco.2021.2323.
Cai E, Garcia J, Liu Y, Vakar-Lopez F, Arora S, Nguyen H
Sci Rep. 2021; 11(1):4609.
PMID: 33633154
PMC: 7907272.
DOI: 10.1038/s41598-021-83662-7.
Grist S, Nasseri S, Laplatine L, Schmok J, Yao D, Hua J
Sci Rep. 2019; 9(1):17782.
PMID: 31780697
PMC: 6883080.
DOI: 10.1038/s41598-019-54001-8.
Shan F, Close D, Camarco D, Johnston P
Assay Drug Dev Technol. 2017; 16(1):27-50.
PMID: 29215913
PMC: 5775115.
DOI: 10.1089/adt.2017.812.
Friesen C, Hormann I, Roscher M, Fichtner I, Alt A, Hilger R
Cell Cycle. 2014; 13(10):1560-70.
PMID: 24626197
PMC: 4050161.
DOI: 10.4161/cc.28493.
Evaluation of therapeutics in three-dimensional cell culture systems by MALDI imaging mass spectrometry.
Liu X, Weaver E, Hummon A
Anal Chem. 2013; 85(13):6295-302.
PMID: 23724927
PMC: 4118837.
DOI: 10.1021/ac400519c.
Penetration of anticancer drugs through tumour tissue as a function of cellular packing density and interstitial fluid pressure and its modification by bortezomib.
Grantab R, Tannock I
BMC Cancer. 2012; 12:214.
PMID: 22672469
PMC: 3407510.
DOI: 10.1186/1471-2407-12-214.
Flow cytometry-assisted Monte Carlo simulation predicts clonogenic survival of cell populations with lognormal distributions of radiopharmaceuticals and anticancer drugs.
Akudugu J, Howell R
Int J Radiat Biol. 2011; 88(3):286-93.
PMID: 22054423
PMC: 4029157.
DOI: 10.3109/09553002.2012.638357.
Identification of a novel topoisomerase inhibitor effective in cells overexpressing drug efflux transporters.
Fayad W, Fryknas M, Brnjic S, Olofsson M, Larsson R, Linder S
PLoS One. 2009; 4(10):e7238.
PMID: 19798419
PMC: 2749935.
DOI: 10.1371/journal.pone.0007238.
Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin.
Markman M
Ther Clin Risk Manag. 2009; 5(1):161-8.
PMID: 19436618
PMC: 2697524.
DOI: 10.2147/tcrm.s4186.
Intraperitoneal drug delivery of antineoplastics.
Markman M
Drugs. 2001; 61(8):1057-65.
PMID: 11465869
DOI: 10.2165/00003495-200161080-00003.
A non-parametric method for the analysis of experimental tumour growth data.
Chignola R, Liberati D, Chiesa E, Anselmi C, Foroni R, SARTORIS S
Med Biol Eng Comput. 2000; 37(4):537-42.
PMID: 10696715
DOI: 10.1007/BF02513343.
Characterization of three-dimensional tissue cultures using electrical impedance spectroscopy.
Kyle A, Chan C, Minchinton A
Biophys J. 1999; 76(5):2640-8.
PMID: 10233078
PMC: 1300233.
DOI: 10.1016/S0006-3495(99)77416-3.
The pH partition theory predicts the accumulation and toxicity of doxorubicin in normal and low-pH-adapted cells.
Gerweck L, Kozin S, Stocks S
Br J Cancer. 1999; 79(5-6):838-42.
PMID: 10070878
PMC: 2362684.
DOI: 10.1038/sj.bjc.6690134.
Drug and radiation resistance in spheroids: cell contact and kinetics.
Olive P, Durand R
Cancer Metastasis Rev. 1994; 13(2):121-38.
PMID: 7923546
DOI: 10.1007/BF00689632.
Inhibition of the regulation of intracellular pH: potential of 5-(N,N-hexamethylene) amiloride in tumour-selective therapy.
Luo J, Tannock I
Br J Cancer. 1994; 70(4):617-24.
PMID: 7917906
PMC: 2033413.
DOI: 10.1038/bjc.1994.360.
Effect of cell density on intracellular adriamycin concentration and cytotoxicity in exponential and plateau phase EMT6 cells.
Chambers S, Bleehen N, Watson J
Br J Cancer. 1984; 49(3):301-6.
PMID: 6704304
PMC: 1976742.
DOI: 10.1038/bjc.1984.47.
Penetration and binding of vinblastine and 5-fluorouracil in cellular spheroids.
Nederman T, Carlsson J
Cancer Chemother Pharmacol. 1984; 13(2):131-5.
PMID: 6467498
DOI: 10.1007/BF00257130.
Pharmacokinetics, binding and distribution of Hoechst 33342 in spheroids and murine tumours.
Olive P, Chaplin D, Durand R
Br J Cancer. 1985; 52(5):739-46.
PMID: 4063148
PMC: 1977212.
DOI: 10.1038/bjc.1985.252.
The response to cytotoxic drugs of EMT6 cells treated either as intact or disaggregated spheroids.
Kwok T, Twentyman P
Br J Cancer. 1985; 51(2):211-8.
PMID: 3966978
PMC: 1977032.
DOI: 10.1038/bjc.1985.31.